Apparatus

HBM1020 is the world's first anti-B7H7 monoclonal antibody to be formally approved for clinical phase.

The US FDA has accelerated the approval of the new drug Pirtobrutinib for the treatment of relapsed or refractory set of cell lymphomas. The drug led to substantial tumour disappearance in 50% of patients, with 13% of them having complete tumour disappearance.

The collaboration aims to improve the efficiency of the drug discovery pipeline by leveraging industry-leading capabilities to identify genetic variants that cause human disease.

Approval for new FIC depression drug on the horizon!

Medical engineers at Walter Reed National Military Medical Center are using additive manufacturing to develop customized prosthetic solutions for veterans. In fact, the center is even operating a 3D Medical Application Center (3DAC). There, a team of specialized engineers and 3D printing technicians are developing customized equipment according to the requirements of veterans.

The Phase I/Ib clinical trial of Mupadolimab, a humanized monoclonal antibody against CD73 and its combination with pablizumab, has received clinical trial approval from the NMPA Pharmacovigilance Center for use in patients with advanced solid tumors.

Was the omission of key data intentional or unintentional?

On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.

The results of a new study recently showed that Olutasidenib monotherapy in patients with relapsed/refractory acute myeloid leukaemia carrying the IDH1 mutation elicited high rates of complete remission with manageable toxicity.

Elahere, the first antibody-coupled drug (ADC) for refractory ovarian cancer, has received accelerated approval from the FDA, resulting in substantial tumour shrinkage in 31.7% of patients and complete tumour disappearance in 4.8%.